Table 3.

The REVEL Trial: Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Non–Small-Cell Lung Cancer

Efficacy measure	Ramucirumab + docetaxel (N = 628)	Placebo + docetaxel (N = 625)
Overall survival
Deaths, N (%)	428 (68)	456 (73)
Median, mo	10.5 (95% CI, 9.5–11.2)	9.1 (95% CI, 8.4–10.0)
Hazard ratio	0.86 (95% CI, 0.75–0.98)
Stratified log-rank P value	.024
Progression-free survival
Events, N (%)	558 (89)	583 (93)
Median, mo	4.5 (95% CI, 4.2–5.4)	3.0 (95% CI, 2.8–3.9)
Hazard ratio	0.76 (95% CI, 0.68–0.86)
Stratified log-rank P value	<.001

CI indicates confidence interval.

Source: Cyramza (ramucirumab) injection prescribing information; December 2014.